Maxim Group Maintains a Hold Rating on Cancer Genetics (CGIX)

By Austin Angelo

In a report released today, Jason McCarthy from Maxim Group maintained a Hold rating on Cancer Genetics (NASDAQ: CGIX). The company’s shares opened today at $0.98, close to its 52-week low of $0.82.

McCarthy observed:

“Cancer Genetics (CGI) announced a collaborative partnership with Cellaria, LLC (private) to enhance the company’s service offerings for discovery and preclinical development in both primary and metastatic solid tumors.”

According to, McCarthy is a 5-star analyst with an average return of 18.3% and a 54.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Cancer Genetics with a $3 average price target.

See today’s analyst top recommended stocks >>

Based on Cancer Genetics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $3.63 million. In comparison, last year the company had a GAAP net loss of $633K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Cancer Genetics, Inc. engages in the development, commercialization, and sale of molecular and biomarker-based tests and services. Through its Select One Clinical Trials program, the firm provides a range of clinical trial services for both oncology and non-oncology genetic testing such as bioinformatics, biomaker solutions, biorepository solutions, consulting, cytogenetics testing, nucleic acid extraction and purification, flow cytometry, Focus::NGS Panel, gene expression analyses, genotyping, and pharmacogenomics. The company was founded by Raju S. K. Chaganti on April 8, 1999 and is headquartered in Rutherford, NJ.